Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Genentech
Massachusetts General Hospital
Brigham and Women's Hospital
New Hampshire Oncology-Hematology PA
Information provided by (Responsible Party):
Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00546156
First received: October 17, 2007
Last updated: March 22, 2013
Last verified: March 2013
  Purpose

Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding to a substance found on cancer cells called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment of breast cancer. Another goal of this research is to determine whether we can develop a way to identify tumors that will respond well to this study treatment.


Condition Intervention Phase
Breast Cancer
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery


Secondary Outcome Measures:
  • Decrease in Interstitial Fluid Pressure. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure


Enrollment: 104
Study Start Date: October 2007
Study Completion Date: December 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: HR+, HER2-
Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
Drug: Doxorubicin
Standard chemotherapy regimen
Other Name: Adriamycin
Drug: Cyclophosphamide
Standard chemotherapy regimen
Other Name: Cytoxan
Drug: Paclitaxel
Standard chemotherapy regimen
Other Name: Taxol
Drug: Bevacizumab
One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
Other Name: Avastin
Active Comparator: Triple Negative Breast Cancer Cohort
Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
Drug: Doxorubicin
Standard chemotherapy regimen
Other Name: Adriamycin
Drug: Cyclophosphamide
Standard chemotherapy regimen
Other Name: Cytoxan
Drug: Paclitaxel
Standard chemotherapy regimen
Other Name: Taxol
Drug: Bevacizumab
One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
Other Name: Avastin

Detailed Description:
  • To prepare for the surgery that will occur at the end of the study treatment, a small "clip" will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer.
  • During the clip placement, a needle will be inserted into the tumor to measure interstitial fluid pressure (IFP measurement). IFP is done for research purposes to help understand how the tumor responds to the study treatment.
  • Study treatment will begin with one dose of bevacizumab alone, followed two weeks later by chemotherapy and bevacizumab in eight two-week cycles. The study treatment will be given intravenously in the clinic.
  • After the first dose of bevacizumab and prior to starting chemotherapy, a needle biopsy of the breast tumor will be performed for research purposes. A second measurement of IFP will also be done at this time.
  • During the treatment period, tests and procedures will be performed at specified intervals and include the following: research MRI, physical exams, blood tests, urine tests, EKG, and MUGA or ECHO.
  • Surgery to remove the tumor will occur no less than four weeks after the last dose of Paclitaxel.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented primary invasive breast cancer by histologic assessment
  • Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis
  • Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol
  • 18 year of age or older
  • Performance status of 0 or 1 by ECOG criteria
  • Use of an effective means of contraception in subjects of childbearing potential
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy.
  • Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment
  • Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer
  • No other malignancy that requires on-going treatment
  • Normal organ function as outlined in the protocol

Exclusion Criteria:

  • Prior cytotoxic chemotherapy or radiation for the current breast cancer
  • Patients with inflammatory breast cancer
  • HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH
  • Known metastatic (Stage IV) disease
  • Other investigational agents within 4 weeks prior to the start of study treatment
  • Life expectancy of less than 6 months
  • Peripheral neuropathy greater than or equal to grade 2
  • Inadequately controlled hypertension
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • NYHA grade II or greater congestive heart failure
  • History of prior myocardial infarction
  • History of unstable angina within 12 months prior to study enrollment
  • Any history of stroke or transient ischemic attack at any time
  • Known CNS disease
  • Significant vascular disease
  • Symptomatic peripheral vascular disease
  • Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study.
  • Known HIV positive
  • Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue
  • Pregnant of lactating
  • Known hypersensitivity to any component of bevacizumab
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00546156

Locations
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber at Faulkner Hospital
Boston, Massachusetts, United States, 02130
United States, New Hampshire
New Hampshire Oncology-Hematology PA
Hooksett, New Hampshire, United States, 03106
Sponsors and Collaborators
Ian E. Krop, MD, PhD
Genentech
Massachusetts General Hospital
Brigham and Women's Hospital
New Hampshire Oncology-Hematology PA
Investigators
Principal Investigator: Ian Krop, MD, PhD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Ian E. Krop, MD, PhD, Medical Oncologist, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00546156     History of Changes
Other Study ID Numbers: 07-130
Study First Received: October 17, 2007
Results First Received: March 22, 2013
Last Updated: March 22, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
ER positive
PR positive

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Bevacizumab
Doxorubicin
Paclitaxel
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents, Phytogenic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on April 20, 2014